Search Within

Mariam Mathew George

Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Department of Medicine (6)
  2. GSK Faculty (6)
  3. Melanoma and Immunotherapeutics Service (6)
  4. Sloan Kettering Institute Postdocs (6)
  5. Solid Tumor Oncology Division (6)
  6. Hematologic Malignancies, Division of (4)

More Groups

People
  1. Jedd Wolchok (6)
  2. Taha Merghoub (6)
  3. Divya Venkatesh (4)
  4. Roberta Zappasodi (4)
  5. Alan Houghton (2)
  6. Allison Betof Warner (2)

More People

Years
  1. 2022 (5)
  2. 2021 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (3)
  2. Cancer Research (2)
  3. Science Translational Medicine (1)
Publishers
  1. Biomed Central Ltd (3)
  2. American Association for Cancer Research (2)
  3. American Association for the Advancement of Science (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model
    Meeting Abstract

    George, M.; Betof, A.; Merghoub, T.; Hamadene, L.; Hirschhorn, D.; Houghton, A.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Apr-246 induces an increase in tumor immunogenicity in a p53 independent manner
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Lu, C.; Budhu, S.; George, M.; Ouerfelli, O.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • APR-246 enhances tumor immunogenicity even in the absence of p53
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Liu, C.; Budhu, S.; George, M. M.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J. D.; Merghoub, T.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model
    Meeting Abstract

    George, M. M.; Warner, A. B.; Hamadene, L.; Hirschhorn, D.; Houghton, A. N.; Wolchok, J. D.; Merghoub, T.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
    Journal Article

    Gigoux, M.; HolmstroĢˆm, M. O.; Zappasodi, R.; Park, J. J.; Pourpe, S.; Bozkus, C. C.; Mangarin, L. M. B.; Redmond, D.; Verma, S.; Schad, S.; more...
    Science Translational Medicine (2022)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; George, M.; Venkatesh, D.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save